NCT02186769View on ClinicalTrials.gov

An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

SchizophreniaSchizoaffective Disorder

Interventions

DRUG

Risperdal® Consta®

DRUG

LY03004

Trial Locations (2)

78754

Community Clinical Research Inc, Austin

92868

Neuropsychiatric Research Center of Orange County, Orange County

All Listed Sponsors

lead

Luye Pharma Group Ltd.

INDUSTRY

NCT02186769 - An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder | Biotech Hunter | Biotech Hunter